Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Escitalopram
100%
Vortioxetine
100%
Subcortical Circuits
100%
Synaptic Integration
100%
Medial Prefrontal Cortex (mPFC)
46%
Nucleus Accumbens
46%
Selective Serotonin Reuptake Inhibitors
30%
5-HT Receptors
30%
Lateral Septal nucleus
23%
Anterior Cingulate Cortex
23%
5-hydroxytryptamine
15%
Receptor Modulation
15%
Hippocampal Fimbria
15%
Evoked Activity
15%
Major Depressive Disorder
7%
Mechanism of Action
7%
No Significant Difference
7%
Treatment Group
7%
Mediating Effect
7%
Executive Function
7%
Partial Agonism
7%
Treatment Impact
7%
Serotonin 5-HT
7%
5-HT Reuptake Inhibitor
7%
5-HT Transporter
7%
5-HT3
7%
5-HT1B Receptor
7%
Mood Disorders
7%
Anesthetized Rats
7%
Receptor Antagonism
7%
5-HT7 Receptor
7%
5-HT1A Receptor
7%
Synaptic Drive
7%
Evoked Response
7%
Electrical Stimulation
7%
Multimodal Action
7%
Complex Modulation
7%
Urethane
7%
Spontaneous Activity
7%
Multimodal Antidepressant
7%
5-HT1D
7%
Receptor Agonism
7%
Neuroscience
Vortioxetine
100%
Escitalopram
100%
Synaptic Integration
100%
Serotonin
69%
Prefrontal Cortex
46%
Nucleus Accumbens
46%
Selective Serotonin Reuptake Inhibitor
30%
Anterior Cingulate Cortex
23%
Septal Nuclei
23%
Receptor Modulation
15%
Receptor
15%
Major Depressive Disorder
7%
Mental Disorder
7%
Evoked Potential
7%
Antidepressant
7%
Partial Agonism
7%
Mood Disorder
7%
5-HT1B Receptor
7%
5-HT1A Receptor
7%
Reuptake Inhibitor
7%
5-HT7 Receptor
7%
Ethyl Carbamate
7%
Executive Function
7%
Electrotherapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Escitalopram
100%
Vortioxetine
100%
Serotonin
69%
Receptor
53%
Selective Serotonin Reuptake Inhibitor
30%
Reuptake Inhibitor
7%
Major Depression
7%
Antidepressant
7%
Mood Disorder
7%
Ethyl Carbamate
7%
Treatment Group
7%
Rat
7%